[Assessment of efficacy of ketoconazole/clindamycin vs metronidazole/nistatine in candidiasic vaginitis and bacterial vaginosis].
Enrique Gómez Bravo Topete, Miguel Garibay Valencia
Abstract
Enrique Gómez Bravo Topete, Miguel Garibay Valencia
Abstract
BACKGROUND: Term vaginitis refers to vaginal mucosa's inflammation, which produces a great variety of symptoms, including: abundant genital draining, of different color, fetid odor, pruritus, irritation, heat, dyspareunia, underwear spotting and frequently it is related to heat when urinating. OBJECTIVE: To compare the ketoconazole/klindamycin vs metronidazole/nistatine efficacy for the treatment of vaginitis. MATERIAL AND METHODS: Efficacy of the ketoconazole/klindamycin vs metronidazole/nistatine combination to treat Candida vaginitis and bacterial vaginosis by vaginal route was compared. Patients with diagnosis of vaginitis and bacterial vaginosis were included in a longitudinal, prospective, double-blind study. Patients were treated with ketoconazole/clindamycin vaginal tablets or metronidazole/ nistatine ovules for 6 days. Patients were evaluated at baseline and at day 7. RESULTS: The global result showed that ketoconazole/clindamycin is superior to metronidazole/nistatine in the treatment of vaginitis/ vaginosis. C. albicans was isolated in 23 patients, 12 in the ketoconazole/clindamycin group and 11 in the metronidazole/nistatine group. At the end of the study, cultures were negative in 66.7% of ketoconazole/clindamycin group and in 54.5% of metronidazole/nistatine group. Eighteen cases presented mixed vaginitis, 13 in ketoconazole/clindamycin group and 5 in metronidazole/nistatine. At the end of the study, culture was negative in ketoconazole/clindamycin (83.3%) group and in all metronidazole/nistatine cases. Anaerobes were isolated in 21 patients, 9 in ketoconazole/clindamycin group and 12 in metronidazole/nistatine. At the end of the treatment, cultures were negative in 77% of ketoconazole/clindamycin group and in 66% of metronidazole/nistatine group; adverse reactions were not reported. CONCLUSION: Treatment with ketoconazole/clindamycin for vaginitis/vaginosis is similar to that of metronidazole/nistatine. Microbiologically and clinically, treatment was well tolerated since there were not adverse reactions during the course of it.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
BACKGROUND: Term vaginitis refers to vaginal mucosa's inflammation, which produces a great variety of symptoms, including: abundant genital draining, of different color, fetid odor, pruritus, irritation, heat, dyspareunia, underwear spotting and frequently it is related to heat when urinating. OBJECTIVE: To compare the ketoconazole/klindamycin vs metronidazole/nistatine efficacy for the treatment of vaginitis. MATERIAL AND METHODS: Efficacy of the ketoconazole/klindamycin vs metronidazole/nistatine combination to treat Candida vaginitis and bacterial vaginosis by vaginal route was compared. Patients with diagnosis of vaginitis and bacterial vaginosis were included in a longitudinal, prospective, double-blind study. Patients were treated with ketoconazole/clindamycin vaginal tablets or metronidazole/ nistatine ovules for 6 days. Patients were evaluated at baseline and at day 7. RESULTS: The global result showed that ketoconazole/clindamycin is superior to metronidazole/nistatine in the treatment of vaginitis/ vaginosis. C. albicans was isolated in 23 patients, 12 in the ketoconazole/clindamycin group and 11 in the metronidazole/nistatine group. At the end of the study, cultures were negative in 66.7% of ketoconazole/clindamycin group and in 54.5% of metronidazole/nistatine group. Eighteen cases presented mixed vaginitis, 13 in ketoconazole/clindamycin group and 5 in metronidazole/nistatine. At the end of the study, culture was negative in ketoconazole/clindamycin (83.3%) group and in all metronidazole/nistatine cases. Anaerobes were isolated in 21 patients, 9 in ketoconazole/clindamycin group and 12 in metronidazole/nistatine. At the end of the treatment, cultures were negative in 77% of ketoconazole/clindamycin group and in 66% of metronidazole/nistatine group; adverse reactions were not reported. CONCLUSION: Treatment with ketoconazole/clindamycin for vaginitis/vaginosis is similar to that of metronidazole/nistatine. Microbiologically and clinically, treatment was well tolerated since there were not adverse reactions during the course of it.
Key concepts: Ketoconazole, Metronidazole, Vaginitis, Clindamycin, Medicine, Bacterial vaginosis, Internal medicine, Antibiotics